pamiteplase

08/01/2000 - "Although occluded coronary arteries reperfused by YM866 (0.1 mg kg(-1) i.v.) treatment 3 h after occlusion did not show an improvement in the LVEF or inhibition of myocardial infarction development, the left ventricular myocardial area and heart mass decreased significantly compared with the vehicle control group 1 week after administration. "
08/01/2000 - "Occluded coronary arteries reperfused by YM866 (0.1 mg kg(-1) i.v.) treatment 30 min after occlusion, by contrast, had improved LVEF and inhibited myocardial infarction development. "
07/01/1998 - "Therefore, YM866 shows promise as an improved clinical agent in treating acute myocardial infarction."
04/01/2000 - "In clinical studies on acute myocardial infarction (AMI), patients were injected with bolus Pamiteplase intravenously at dosages of 0.05, 0.1, or 0.2 mg/kg-body weight. "
07/01/1998 - "In conclusion, although both YM866 and alteplase reperfused occluded coronary arteries, inhibited myocardial infarct development and improved LVEF in dogs with coronary artery thrombi, only a single bolus injection of YM866 was necessary to achieve these improvements. "

03/05/2001 - "Protective effects of pamiteplase, a modified t-PA, in a rat model of embolic stroke."
03/05/2001 - "The effects of alteplase (tissue plasminogen activator, t-PA) and pamiteplase (a modified t-PA with longer half-life and increased potency) were compared in a clinically relevant model of embolic stroke. "

03/15/2001 - "The pharmacokinetic parameters distribution volume at the steady state and CL(total) calculated by immunoreactive concentration after administration of pamiteplase to rats, dogs, and monkeys show high correlation with body weights (r(2)=.7728 and .9039)."
04/01/2000 - "In clinical studies on acute myocardial infarction (AMI), patients were injected with bolus Pamiteplase intravenously at dosages of 0.05, 0.1, or 0.2 mg/kg-body weight. "

03/15/2001 - "The data suggest that a bolus administration of pamiteplase shows the same thrombolytic activity as continuous infusion of rt-PA in experimentally induced thrombosis in rats and dogs. "
10/01/1996 - "One hour after thrombus formation, YM866 was administered by intravenous bolus injection, while tPA was given by the same method or by 60-min infusion under adequate heparinization. "
10/01/1993 - "We compared the thrombolytic activity of a novel modified t-PA, YM866, with that of t-PA in a rat model of electrically-induced thrombosis. "
10/01/1996 - "We have compared the thrombolytic effect of such a mutant, YM866, with that of tPA in copper-coil-induced femoral arterial thrombosis in dogs. "
10/01/1996 - "Comparative study of a mutant tissue-type plasminogen activator, YM866, with a tissue-type plasminogen activator in a canine model of femoral arterial thrombosis."

07/01/2003 - "Thus, bolus injection of pamiteplase can reduce infarction volume suppressing the incidence of hemorrhage."
07/01/2003 - "Infarction volume was significantly reduced by the early administration of pamiteplase at 2 h after the onset of ischemia. "
07/01/2003 - "Reduction of infarction volume by bolus injection of pamiteplase, a modified tissue plasminogen activator with a longer half-life."
03/05/2001 - "However, there was good correlation between 24 h residual clot grades and infarct volumes, suggesting a delayed timeframe for pamiteplase- and alteplase-induced reperfusion."
07/01/2003 - "Using a rat model of thromboembolic stroke we evaluated whether or not fibrinolysis by bolus injection of pamiteplase, a modified tissue plasminogen activator (tPA) with a longer half-life, reduces infarction volume. "